Dr. Till on the Durability of Response With Brexucabtagene Autoleucel in MCL

Partner | Cancer Centers | <b>SCCA</b>

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

Brian Till, MD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the potential durability of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma (MCL).

In July 2020, brexucabtagene autoleucel received FDA approval for the treatment of patients with relapsed/refractory MCL based on findings from the phase 2 ZUMA-2 trial, in which the CAR T-cell product elicited an 87% objective response rate in this patient population.

However, without long-term data, the durability of these responses remains largely unknown, says Till. Unlike large-cell lymphoma which can be cured, MCL and follicular lymphoma are considered incurable diseases with currently available therapies, Till explains. Currently, some patients appear to have late relapses after CAR T-cell therapy, but whether the survival curve will plateau or many patients will relapse can only be answered with additional follow-up, concludes Till.